Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for severe COVID-19 pneumonia
ChiCTR2300069639Phase 2Not yet recruiting
- Sponsor
- Changsha Taihe Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia comparing Jaktinib 100 mg BID with Placebo (2 arms). Primary endpoints: Proportion with progression to critical illness or all-cause mortality by Day 28, Proportion with progression to critical illness or all-cause mortality by Day 14 and 4 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2300069639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069639.